CRAFA
PEPTIDE & COMPOUND ANALYSIS

CERTIFICATE OF ANALYSIS

Certificate of Analysis (COA)

No. CRF-2026-1064
Issued: 2026-10-05

Independent Peptide & Research-Compound Testing
14 Mill Lane, Cambridge, United Kingdom

PRODUCT IDENTIFICATION

PRODUCT Retatrutide + Cagrilintide 5mg/5mg	SKU / INTERNAL CODE CRF-RETATRUTIDEC	PRESENTATION Lyophilised powder, 5mg/5mg vial
BATCH NUMBER LOT-2610-064	SAMPLE RECEIVED 2026-09-28	PRODUCTION DATE 2026-09-25
ANALYSIS DATE 2026-10-03	EXPIRY / RETEST DATE 2028-10-03	MOLECULAR FORMULA Blend (C221H342N46O68 + C194H312N54O59S2)
MOLECULAR WEIGHT (G/MOL) N/A	CAS N/A	

Research Use Only (RUO). Not for human or veterinary use, consumption, or clinical diagnosis.

ANALYTICAL METHOD — HPLC

INSTRUMENT Waters Xevo G3	COLUMN C4 2.1×100mm	COLUMN TEMPERATURE 60°C
MOBILE PHASE A 0.1% TFA H2O	MOBILE PHASE B ACN	FLOW RATE 0.3 mL/min
DETECTION WAVELENGTH 214 nm	INJECTION VOLUME 5 µL	SAMPLE CONCENTRATION 0.5 mg/mL
DILUENT —	RETENTION TIME (MAIN PEAK) 14.2 / 12.1 min	

Recorded methods: HPLC-UV (214 nm) · LC-MS/MS · LAL · ICP-MS

RESULTS

Test	Acceptance Criteria	Result	Verdict
HPLC Purity (% area)	≥98.0%	99.2%	PASS
Identity (LC-MS)	4732.4 & 4410.0 ±2%	Obs: 4732.8 / 4410.4 [M+H]+	PASS

Test	Acceptance Criteria	Result	Verdict
Quantity found	95.0–105.0%	9.90 mg (99.0%)	PASS
Endotoxin	<1.0 EU/mg	<0.25 EU/mg	PASS
Heavy metals	<10 ppm	All <LOQ	PASS

Detected Impurities

No impurity data recorded.

FINAL BATCH RESULT

PASS — Conforms to specifications

No chromatogram data recorded.

Analyst notes: Category: Specialty. Sample conforms to label claim and Gold panel acceptance criteria.

crafa

CRAFA